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Background: Induced regulatory T (iTreg) lymphocytes show promise for application in the treatment of allergic,
autoimmune and inflammatory disorders. iTreg cells demonstrate advantages over natural Treg (nTreg) cells in
terms of increased number of starting population and greater potential to proliferate. Different activation methods
to generate iTreg cells result in iTreg cells that are heterogeneous in phenotype and mechanisms of suppression.
Therefore it is of interest to explore new techniques to generate iTreg cells and to determine their physiological
relevance.
Methods: Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we
generated in vitro functional CD4+CD25+ iTreg (TregPMA) cells. Functionality of the generated TregPMA cells was
tested in vivo in a mouse model of inflammatory bowel disease (IBD) - CD45RB transfer colitis model.
Results: TregPMA cells expressed regulatory markers and proved to ameliorate the disease phenotype in murine
CD45RB transfer colitis model. The body weight loss and disease activity scores for TregPMA treated mice were
reduced when compared to diseased control group. Histological assessment of colon sections confirmed
amelioration of the disease phenotype. Additionally, cytokine analysis showed decreased levels of proinflammatory
colonic and plasma IL-6, colonic IL-1 β and higher levels of colonic IL-17 when compared to diseased control
group.
Conclusions: This study identifies a new method to generate in vitro iTreg cells (TregPMA cells) which physiological
efficacy has been demonstrated in vivo.
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T regulatory (Treg) lymphocytes are a cellular compo-
nent of the immune system responsible for suppressing
immune responses of effector cells. As a result of their
ability to control immune responses and to sustain sys-
temic immune balance, they have the potential to pre-
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reproduction in any medium, provided the or[1-10] as well as to be an adjuvant therapy for chronic
and acute graft versus host disease [11].
The safety profile of Treg cells has been established in
phase I clinical trials [11,12] demonstrating that Treg
cells are a suitable candidate for therapeutic purposes.
However a major limitation to the clinical use of natural
Treg (nTreg) cells is their low availability as they repre-
sent only a small percentage of the peripheral circulating
CD4+ T cell population. In order to overcome this issue,
several groups have developed methods to expand nTreg
cells in vitro when keeping their functionality. Generally
the technologies are complex, time-consuming and theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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during ex vivo expansion can lead to loss of their sup-
pressive activity [13]. Furthermore their stage of differ-
entiation makes their expansion in vitro a difficult
process [14].
In vitro induced T regulatory (iTreg) cells represent a
good alternative to nTreg cells since they have been
reported to have similar functionality in in vivo setup.
Additionally iTreg cells show advantages over nTreg
cells in terms of increased number of starting population
and greater potential to proliferate [15]. Therefore it is
of importance to investigate and explore new approaches
to generate iTreg cells.
Based on the activating and stimulating properties of
phorbol myristate acetate (PMA)/ionomycin and anti-
CD3 on T cells [16,17] we developed a new method to
generate iTreg cells in vitro, which we refer to as
‘TregPMA’ cells. The functionality of the TregPMA cells




BALB/C and C.B.-17 SCID mice (8–10 weeks) were
obtained from Harlan and maintained in specific
pathogen-free conditions. Mouse experiments were
approved by the local animal welfare committee (Univer-
sity of Amsterdam).
Generation of regulatory T lymphocytes (Treg PMA cells)
Splenocytes were isolated from BALB/C mice. CD4+
CD25- T cells were isolated from splenocytes by means
of negative selection using the mouse “CD4+ T Cell Iso-
lation Kit” followed by “CD25 MicroBead Kit” (Miltenyi
Biotec). Cells were seeded at day 0 at 1x105/well into
anti-CD3e (0.5 μg/well, clone 145-2C11, eBioscience)
coated 96-well flat bottom plates (Costar) and cultured
in X-VIVO 15 medium (Lonza) at 37°C in a 5% CO2
incubator. On day 1, cells were activated with PMA
(10 ng/ml) and ionomycin (250 ng/ml) and at day 2, 3
and 4 supplemented with 20 U/well of IL-2 (eBioscience).
On day 5, prior to use, cells were harvested and treated
with “Dead Cell Removal Kit” (Miltenyi Biotec).
Flow cytometry analysis
Cells were analyzed using flow cytometry (FACSCalibur,
BD Biosciences). For Treg cell staining the mouse
“Regulatory T cell Staining Kit” was used which con-
sisted of anti-mouse CD4 FITC (clone RM4-5), anti-
mouse CD25 APC (clone PC61.5) and anti-mouse/rat
Foxp3 PE (clone FJK16). Additional monoclonal anti-
mouse flow cytometry antibodies used in this study were
as follows: anti-mouse CD152 (CTLA-4) APC (clone
UC10-4B9), anti-mouse GARP PE (clone YGIC86), anti-mouse/rat CD278 (ICOS) FITC (clone C398.4A) and
anti-mouse CD134 (OX-40) APC (clone OX86). All anti-
bodies were obtained from eBioscience.
Induction of CD45RB transfer colitis model and treatment
with TregPMA cells
Chronic colitis was induced in C.B.-17 SCID mice by
intraperitoneal (IP) injection of CD45RBhigh cells (4x
105) isolated from normal BALB/C mice splenocytes
(positive control group). Mice that received CD45RBhigh
cells in combination with CD45RBlow cells (2x105) were
protected from disease development (negative control
group). The treatment group received CD45RBhigh cells
in combination with in vitro generated TregPMA cells
(TregPMA cell treated group). The amount of TregPMA
cells injected per mouse was 1.2x106.
Monitoring development of colitis
The primary read-out to assess the development of col-
itis was the body weight loss. Mice were weighed three
times a week. Body weight loss was determined by per-
centage of weight loss from base line body weight.
After sacrifice, colon was excised and longitudinally
divided into 2 parts both of which were rolled up: one
was used for preparation of paraffin embedded samples
while the other was snap frozen in liquid nitrogen. Dis-
ease activity index (DAI) was calculated by combining
the scores applied to weight loss (0: <1%; 1: 1-5%; 2: 5-
10%; 3: 10-15%; 4: >15%), stool consistency at sacrifice
(0: normal; 1: loose droppings; 2: loose stools, colon
filled with feces; 3: loose stool, feces only near caecum,
4: empty bowel) and rectal bleeding (0: negative; 2: posi-
tive; 3: gross bleeding) divided by three.
Histology
The half divided colon tissue was fixed in 4% paraformal-
dehyde and embedded in paraffin. The colon tissue was
cut in 5 μm sections and stained with hematoxylin and
eosin for histological scoring. An experienced pathologist
blinded to experiment inspected microscopically all sec-
tions and graded them on a scale 0 to 4 looking at:
mononuclear and polymorphonuclear infiltrate, goblet
cell depletion, crypt loss, epithelial hyperplasia, presence
of ulcerations and manifestations of crypt abscesses.
Cytokine analysis
Frozen colon tissue was crushed with the use of Cryo-
Prep™ System (Covaris) and resuspended in ice-cold PBS
(pH 7.2) containing complete protease inhibitor (Roche).
Homogenates were then centrifuged at 15000 x g for
5 min at 4°C and the supernatants were stored at −80°C
until the cytokine assay. Prior to cytokine analysis total
concentration of the protein in supernatants was deter-
mined with the use of Bradford assay (Biorad). Colonic
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TNF-α were analyzed using a mouse cytokine magnetic
bead-based multiplex assay (Biorad) according to the
manufacturer’s instructions. Additionally TGF-β levels
were analyzed with Bio-Plex Pro TGF-β assay (Biorad)
according to manufacturer’s instructions.
Statistical analysis
Data were analyzed statistically and graphed using
Prism 5.0 (GraphPad Software). Changes in mice weekly
body weight, body weight at sacrifice, disease activity
index (DAI), histological score and cytokine levels are
shown as mean ± standard deviation (SD) and analyzed
by one-way ANOVA, followed by Bonferroni’s Multiple
Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
Results
CD4+CD25- T cells acquire a regulatory T cell phenotype
through PMA/ionomycin/anti-CD3 mediated activation
In order to generate regulatory T cells, CD4+CD25- cells
from BALB/C mice were activated overnight on 96-wellFigure 1 CD4+CD25- cells acquire regulatory phenotype- CD4+CD25hi
in culture, the CD4+CD25- T cells were analyzed by flow cytometry and 85.
co-express CD4 and CD25 marker (A) and mean of 36.86 ± 7.46% of the ce
Three independent experiments were performed (A, B). Representative ove
(in blue) PMA/ionomycin/anti-CD3 activation and 5 days in culture. One repre
CD25+ cell population (D).plate coated with anti-CD3. Subsequently PMA/ionomy-
cin and IL-2 were added to the cell culture. After 5 days
in culture, the cells were analyzed for their phenotype by
flow cytometry. Between 85.26% and 91.85% of the cul-
tured cells were shown to up-regulate and co-express
the CD4 and CD25 markers (mean 91.4 ± 5.9%, n = 3,
see: Figure 1A, C). The absence of PMA/ionomycin ac-
tivation step on CD4+CD25- cells resulted in significant
decrease in cell viability (data not shown) which con-
firms the necessity of additional activation with PMA/
ionomycin.
Additionally, we analyzed the expression of Foxp3,
CTLA-4, GARP, ICOS and OX-40 markers which are
known to be associated with a T regulatory cell pheno-
type and function [18-22]. All tested markers were found
to be up-regulated in ~30% of the CD4+CD25+ T cells
after activation (a representative result is shown in
Figure 1D, Figure 2A, B, C, D).
Similarly to previously reported data with iTreg cells
generated in vitro [23], the cellular level of Foxp3 ex-
pression in the cells activated with PMA/ionomycin/
anti-CD3 appears to be low (see: Figure 1B, D).ghFoxp3+. After activation with PMA/ionomycin/anti-CD3 and 5 days
26% to 91.85% (mean: 91.4 ± 5.9%, n = 3) of the cells were shown to
lls acquire the classical regulatory phenotype- CD4+CD25highFoxp3+ (B).
rlays of CD25 histograms (C) and Foxp3 (D) before (in red) and after
sentative experiment is shown. Foxp3 histogram was gated on CD4+
Figure 2 CD4+ CD25- cells up-regulate markers associated with regulatory phenotype. TregPMA cells express the markers CTLA-4 (A), GARP
(B), ICOS (C) and OX40 (D) associated with a regulatory phenotype and function. Representative histogram overlays are shown. In red CD4+CD25-
T cells at time 0 and in blue TregPMA cells after following PMA/ionomycin/anti-CD3 activation and 5 days in culture.
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cin/anti-CD3 activation (iTreg cell population) as
‘TregPMA’ cells.
TregPMA cells ameliorate the disease phenotype in a
colitis transfer mouse model
IBD was induced in C.B-17 SCID mice by transfer of
CD45RBhigh cell population from BALB/C mice (positive
control group) and was prevented by co-transfer of
CD45RBlow cell population (negative control group)
[24-27].
The read-out parameters of the development and pro-
gression of the colitis in the transfer mouse model are
body weight loss and inflammation of the intestinal
tissue.
The positive control group developed colitis and pre-
sented a relative decrease of initial body weight 86.88 ±
5.06% (n = 9) at sacrifice which was significantly lower
than the negative control that reached 110 ± 3.29% (n =
10) of the initial body weight. The TregPMA cell treat-
ment (injection of TregPMA cells together withCD45RBhigh cells) reduced significantly the body weight
loss to 99.18 ± 7.17% (n = 10) as compared to the posi-
tive control group (Figure 3A, B).
The Disease Activity Index (DAI), which is an indicator
of colonic inflammation, reflecting weight loss, stool
consistency and presence of rectal bleeding was deter-
mined at sacrifice. The DAI was significantly lower in mice
treated with TregPMA cells (1.18 ± 0.55) when compared
to the positive control group (2.04 ± 0.35), confirming the
amelioration of the disease phenotype (Figure 3C).
Intestinal inflammation was further determined by
histopathological analysis of colon tissue post mortem
which includes evaluation of mononuclear and poly-
morphonuclear cell infiltrate, goblet cell depletion, loss
of crypts, epithelial hyperplasia and manifestations of
ulcerations and abscesses [24-27].
A significant reduction of inflammation was observed
in the colon tissue of the TregPMA cell treated mice
when compared to the positive control group (Figure 3D).
The spread of intestinal inflammation was less exten-
sive and no ulcerations were observed in the TregPMA
Figure 3 Amelioration of the disease phenotype in TregPMA cell treated mice. Mice that were injected with CD45RBhigh cells only
developed colitis (positive control group, n = 9) while the mice that were injected with CD45RBhigh and CD45RBlow cells together remained
healthy (negative control group, n = 10). The experimental group was injected with CD45RBhigh and TregPMA cells (n = 10). Disease progression
was assessed by changes in weekly body weight (A) as well as macroscopic and microscopic scores at day of sacrifice which comprises of
Disease Activity Index (C) and Histological Score (D). TregPMA cell treated mice showed to have reduced weight loss over time (A) and at the
time of sacrifice (B) when compared to positive control. The change of weight is expressed as the mean percentage of initial weight per group ±
SD. Disease Activity Index (DAI), calculated from combining scores applied to weight loss, stool consistency at sacrifice and rectal bleeding
divided by three, shows a significant difference between groups (C) as well as Histological Score of the H&E stained colon tissue sections (D). The
data were analyzed using one-way ANOVA, followed by Bonferroni’s Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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control group (Figure 4A) while in the diseased control
group they were commonly present (Figure 4C).
Proinflammatory cytokine production in colon and in
plasma of TregPMA cell treated mice is reduced
We next examined the influence of TregPMA cell treat-
ment on the production of pro-inflammatory cytokines
IL-6, IL-1β and TNF-α that have been previously
described to be increased in CD45RB transfer colitis
mouse model [28,29]. The level of IL-10 and TGF-β that
have been shown to have a regulatory effect in experi-
mental colitis were also analyzed [30,31]. Additionallythe level of IL-17 cytokine that have been described to
have both pro- and anti-inflammatory effect in IBD was
measured [30,32-35].
The level of IL-6 was found to be decreased in
TregPMA cell treated group in both colon homogenates
and plasma at the day of sacrifice when compared to the
positive control group (Figure 5A, D). IL-1β level was
also found to be reduced after TregPMA cell treatment
in colon homogenates but this decrease was not
reflected in plasma (Figure 5B, E).
Elevated levels of IL-17 were found in colon tissue
homogenates of TregPMA cell treated mice as well as in
positive control group. However, the TregPMA cell
Figure 4 Histopathology of mouse colon. Representative whole-colon photographs of H&E stained tissue sections of negative control mouse
(A), TregPMA cell treated mouse (B) and positive control mouse with ulceration manifestation (C).
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positive control (Figure 5C). No significant difference
between groups was observed in the levels of IL-17 ex-
pression in plasma (Figure 5F).
TNF-α, IL-10 and TGF-β levels in both colon homoge-
nates and plasma showed no significant differences be-
tween groups (data not shown).
Discussion
In this article we describe the generation of iTreg
cells (TregPMA cells) in vitro from CD4+CD25- cells
by PMA/ionomycin/anti-CD3 activation based method.
Several other groups have explored different strategies
to generate iTreg from naive T cells in vitro, includ-
ing use of TGF-β, all-trans-retinoic acid and the re-
cently discovered regulatory cytokine IL-35 [36,37].
However, all these methods are more or less impeded
with their own limitations [16]. Therefore, there is
need for improvement in this field and our group
designed and explored a new method of in vitro
iTreg cells (TregPMA) generation which we report in
this manuscript.
Mechanistically, PMA/ionomycin provides a potent
stimulation allowing us to bypass the T cell receptor ac-
tivation essential for Treg cell development and it pre-
vents the emergence of CD4-CD8+ cells in the culture
[17]. PMA activates protein kinase C [38] while ionomy-
cin is a Ca2+ mobilizing agent [39]. This combination
has been shown to up-regulate CD25 on T lymphocytes
[17] and a high CD25 expression is a marker of the Tregcell phenotype [40]. Additionally, it was demonstrated
that Ca2+ signaling is required for the development and
function of Treg cells [41,42]. Therefore we expected
that raising the intracellular levels of Ca2+ in naive T
cells using ionomycin would have a synergistic effect
with PMA in starting a regulatory developmental pro-
gram in CD4+CD25- cells. Additionally a low dose of IL-
2 was used in cell culture since IL-2 is important for
Treg cell homeostasis and maintaining their suppressive
survival program [43] while anti-CD3 which is also
present in the cell culture has been shown to maintain
and expand Treg cells [44], however use of only anti-
CD3 and IL-2 for in vitro CD4+CD25- cell stimulation
resulted in low cell viability and poor regulatory markers
expression which indicates that additional stimulation
with PMA/ionomycin is needed.
The TregPMA cells up-regulate CD25, and ~30% of
the CD4+CD25+ T cells up-regulate CTLA-4, GARP,
ICOS, OX-40 and Foxp3 which are important markers
associated with regulatory cell phenotype and function
[18-22,45,46]. Interestingly, the level of Foxp3 expression
in TregPMA cells is quite low. Although Foxp3 expres-
sion is considered to be a main characteristic of Treg
cells, Treg cells are recognized to be a heterogeneous
cell population. Especially, it has been reported that
CD4+CD25+ Foxp3- cell population also can present
regulatory function in vitro and in vivo [23].
The functionality of the TregPMA cells has been
demonstrated in vivo by their potential to ameliorate the
disease phenotype in a CD45RB transfer colitis mouse
Figure 5 Cytokine levels in mouse colon homogenates and plasma. Colonic tissue homogenates and plasma levels of IL-1β (A, D), IL-6 (B, E)
and IL-17 (C, F) of negative control group (n = 10), TregPMA cell treated group (n = 10) and positive control group (n = 9) were analyzed using a
mouse cytokine magnetic bead-based multiplex assay. TregPMA cell treatment has shown to suppress increased levels of colonic IL-1β (A), IL-6
(B) and plasma IL-6 (E) in CD4+CD45RBhigh CD25- cell transferred colitic mice. The data were analyzed using one-way ANOVA, followed by
Bonferroni’s Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000.
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ation of the disease phenotype observed in the group
of mice treated with the TregPMA cells does not par-
tially involve cell types, other than regulatory, present
in the cell suspension injected. Indeed, high numbers
of CD45RBhigh cells (6x106/mouse) have been shown
to reduce the severity of the disease in a mouse model
of colitis [47]. However, in our study, the total number
of cells injected (1,2x106/mouse) was significantly
lower and the amelioration of the severity of the dis-
ease was observed in all of the treated animals (n = 10)
against 3 out of 5 in the mentioned study. All to-
gether, these data suggest that the observed protective
effect is mostly related to TregPMA cells.
The disease amelioration after TregPMA treatment
was accompanied by a decrease of the pro-inflammatory
IL-1 β levels in the colon tissue which reflect the severity
of experimental colitis [28]. Such a decrease in IL-1β
was previously reported by Hirano and Kudo after treat-
ment of CD45RB transfer colitis mouse model with bothdexamethasone and anti-tumor necrosis factor-α (anti-
TNF-α).
IL-1β stimulates the production of the pro-
inflammatory cytokine IL-6 [48] which has been
described to be up-regulated in mouse model of IBD
[49] and in human ulcerative colitis or Crohn’s disease
patients [50]. Simultaneously with the decrease of IL-1β
in our study, IL-6 levels were found to be reduced in
both colonic homogenates and plasma samples after
treatment with TregPMA cells.
The concentration of IL-17 was found to be more ele-
vated in colon homogenates of TregPMA cell treated
mice than in the positive control group. Although the
role of this cytokine in the initiation or pathogenesis of
IBD is controversial, a protective function of IL-17 in
the gut of CD45RB transfer colitis model has been previ-
ously noted [30,33,51]. Several groups have reported that
both IL-17−/− CD45RBhigh and IL-17R−/− CD45RBhigh
cells induce a more aggressive disease phenotype than
wild type CD45RBhigh cells [30,51]. Accordingly, our
Majowicz et al. BMC Gastroenterology 2012, 12:172 Page 8 of 9
http://www.biomedcentral.com/1471-230X/12/172results show that an increased IL-17 level also correlated
with less severe intestinal inflammation and lack of
ulcerations.
IL-10 and TGF-β cytokine level in both mouse plasma
and colon homogenates show no significant differences
between experimental groups at the time of experiment
termination (week 7). However, it does not exclude the
possible influence of those cytokines on prevention of
the colitis induction at earlier time point.
The cells that have been found mostly responsible for
pathogenesis of CD45RB transfer model of IBD are Th1
cells. Recently it has been shown that IL-17 blocks the
Th1 cell development in vivo via IL-17R on naive CD4+
T cells [30,51]. In the TregPMA cell treated group we
also observe elevated level of IL-17 which correlates with
disease amelioration. IL-17 can be produced by many
types of cells among which are also T regulatory cells
[52]. Therefore we are hypothesizing that in vivo disease
amelioration by TregPMA cells is IL-17 mediated. As
follow-up to this study, physiological relevance of
TregPMA cells and their exact molecular mechanism of
action needs to be determined.
Conclusions
Induced regulatory T cells are promising tools for thera-
peutic applications in IBD [53] as well as in other auto-
immune disorders and are of great scientific interest.
Many techniques to generate inducible Treg cells from
naive T cells have been developed and described
[8,36,37,54,55]. Different activation methods to generate
iTreg cells result in iTreg cells that are heterogeneous in
phenotype. The in vitro PMA/ionomycin/anti-CD3 acti-
vation of CD4+CD25- T cells has proven to generate
functional iTreg cells (TregPMA cells) but the in vivo
physiological relevance of TregPMA cell signaling needs
to be further investigated.
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